期刊文献+

人乳头瘤状病毒疫苗 被引量:1

原文传递
导出
摘要 小儿喉乳头状瘤与人乳头状瘤病毒6、Ⅱ型感染有关,一种预防宫颈癌的疫苗产生的免疫作用不仅针对导致宫颈癌的常见病毒亚型并且包含了与小儿喉乳头状瘤相关的病毒亚型,应用此类疫苗必将会为防治人乳头状瘤病毒6、Ⅱ亚型感染及其相关疾病提供更加有效的方法。
作者 谷曼丽 王军
出处 《国际耳鼻咽喉头颈外科杂志》 2009年第3期181-184,共4页 International Journal of Otolaryngology-Head and Neck Surgery
  • 相关文献

参考文献23

  • 1Lee JH, Smith RJ. Recurrent respiratory papillomatosis: pathogenesis to treatment. Curr Opin Otolaryngol Head Neck Surg, 2005, 13 (6) : 354-359.
  • 2Silverberg MJ, Thorsen P, Lindeberg H, et al. Clinical course of recurrent respiratory papitlomatosis in Danish children. Arch OtolaryngolHeadNeckSurg, 2004, 130 (6) : 711-716.
  • 3Shah KV, Unger ER, Derkay CS, et al. Recurrent respiratory papillomatosis., bright prospects for vaccine-based prevention. PapillomavimsRep, 2005, 16: 333-338.
  • 4Parkin DM, Bray F. The burden of HPV-related cancers. Vaccine, 2006, 24 (Suppl3) : S11-S25.
  • 5Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. JClinInvest, 2006, 116 (5) : 1167-1173.
  • 6Pinto LA, Edwards J, Castle PE, et al. Cellular immune responses to human papillomavirus (HPV) -16 El in healthy volunteers immunized with recombinant HPV-16 L 1 virus-like particles. J Infect Dis, 2003, 188: 327-338.
  • 7Ault KA, Giuliano AR, Edwards RP, et al. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine, 2004, 22 (23-24) : 3004-3007.
  • 8Fife KH, Wheeler CM, Koutsky LA, et al. Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women. Vaccine, 2004, 22 (21-22) : 2943-2952.
  • 9陈波蓓,赵孔南,刘晓松,许燕,项松洁,杨继红,陈小芳.HPV6b病毒样颗粒免疫治疗儿童喉乳头状瘤临床初步研究[J].临床耳鼻咽喉科杂志,2004,18(9):516-518. 被引量:4
  • 10Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet, 2004, 364 (9447) : 1757-1765.

二级参考文献7

  • 1刘跃华,刘晓松,IanH.Frazer.人乳头瘤病毒6b型病毒样颗粒免疫活性的研究[J].中华医学杂志,2002,82(9):587-589. 被引量:7
  • 2Tindlle R W. Immunomanipulative strategies for the control of human papillomavirus associatedl cervical disease. Immunol Res, 19997,16: 387- 400.
  • 3Breitburd F, Coursaget P. Human papillomavirus vaccines. Semin Cancer Biol, 19999, 99 : 435 - 444.
  • 4Zhang L F,Zhou J,Chen S,et al. HPV6b viruslike particles are potent immunogens without adjuvant in man.Vaccine, 2000,18 : 1051- 1058.
  • 5Peng S W, Frazer I H, Zhou J. Papillomavirus viruslike particles can deliver defined CTL epitopes to the MHC class I pathway. Virology, 1998,240:147-157.
  • 6Brown D R,Bryan J T,Schroeder J M. Neutralization of human papillomavirus type 11 (HPVll) by serum from women vaccinated with yeast-derived HPVllL1 viruslike particles. J Infect Dis, 2001,184 : 1183- 1186.
  • 7Koutsky L A, Ault K A,Wheeler C M, et al. A controlled trial of a human papillomavirus type 16 vaccine.N Engl J Med,2002,347:1645-1651.

共引文献3

同被引文献4

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部